person · Reporting owner

Dable Habib J

Disclosed activity across 10 companies

Tapewire entity: 36338
SEC CIK: 0001690773

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Jade Biosciences, Inc.AVTE · Entity 4757	Director	June 05, 2024	June 07, 2024
PepGen Inc.PEPG · Entity 6253	Director	June 18, 2026	June 22, 2026
Relay Therapeutics, Inc.RLAY · Entity 4044	Director	June 09, 2026	June 10, 2026
SpyGlass Pharma, Inc.SGP · Entity 5034	Director	February 05, 2026	February 09, 2026
Tempest Therapeutics, Inc.MLND · Entity 7734	Director	June 22, 2020	June 23, 2020
Tyra Biosciences, Inc.TYRA · Entity 4680	Director	April 16, 2026	April 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Jade Biosciences, Inc.

Report date June 05, 2024 · Filed June 07, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2034-06-04	Direct	12,500	Reported balance After 2024-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-05 · Grant · Acquired 12,500 · Balance 12,500 F1: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

PepGen Inc.

Report date June 18, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2036-06-17	Direct	34,000	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 34,000 · Balance 34,000 F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

Relay Therapeutics, Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-08	Direct	32,947	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 32,947 · Balance 32,947 F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

SpyGlass Pharma, Inc.

Report date February 05, 2026 · Filed February 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-05	Direct	27,400	Reported balance After 2026-02-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-05 · Grant · Acquired 27,400 · Balance 27,400 F1: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026.

Tempest Therapeutics, Inc.

Report date June 22, 2020 · Filed June 23, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2030-06-21	Direct	12,000	Reported balance After 2020-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-22 · Grant · Acquired 12,000 · Balance 12,000 F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.

Tyra Biosciences, Inc.

Report date April 16, 2026 · Filed April 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.12 · Expires 2036-04-15	Direct	44,400	Reported balance After 2026-04-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-16 · Grant · Acquired 44,400 · Balance 44,400 F1: 1/36th of the total number of shares of common stock subject to the option vest monthly following April 16, 2026, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/36th of the total number of shares of common stock subject to the option vest monthly following April 16, 2026, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACCELERON PHARMA INC

Report date November 19, 2021 · Filed November 22, 2021

Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-19 transaction · row 1 1 source row Row 1 · 2021-11-19 · Other · Disposed 98,450 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $35.04	Direct	Reported balance After 2021-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-19 · Disposition to issuer · Disposed 250,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61	Direct	Reported balance After 2021-11-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-19 · Disposition to issuer · Disposed 108,800 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64	Direct	Reported balance After 2021-11-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-19 · Disposition to issuer · Disposed 106,400 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99	Direct	Reported balance After 2021-11-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-11-19 · Disposition to issuer · Disposed 84,720 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53	Direct	Reported balance After 2021-11-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-11-19 · Disposition to issuer · Disposed 64,361 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

ALBIREO PHARMA, INC.

Report date March 02, 2023 · Filed March 02, 2023

Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.86 · Expires 2032-08-07	Direct	0	Reported balance After 2023-03-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-03-02 · Disposition to issuer · Disposed 16,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") F2: (Continued from above) and thereafter merged with and into the Issuer (the "Merger"), effective March 2, 2023 (the "Effective Time"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest F3: (Continued from above) upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share")

F2: (Continued from above) and thereafter merged with and into the Issuer (the "Merger"), effective March 2, 2023 (the "Effective Time"). At the Effective Time, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such In the Money Option immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest

F3: (Continued from above) upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration and had no further force or effect.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-07-17 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-07-17 · Disposition to issuer · Disposed 3,902 · Balance 8,742 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration. Row 2 · 2025-07-17 · Other · Disposed 8,742 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.38	Direct	Reported balance After 2025-07-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-17 · Disposition to issuer · Disposed 7,950 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.66	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 4,570 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Day One Biopharmaceuticals, Inc.

Report date April 23, 2026 · Filed April 23, 2026

Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-01-16	Direct	Reported balance After 2026-04-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-23 · Disposition to issuer · Disposed 66,660 · Balance 0 F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F1: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-05-22	Direct	Reported balance After 2026-04-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-23 · Disposition to issuer · Disposed 32,335 · Balance 0 F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The options are fully vested.
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2035-06-01	Direct	Reported balance After 2026-04-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-23 · Disposition to issuer · Disposed 22,500 · Balance 0 F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2026-04-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-23 · Disposition to issuer · Disposed 15,000 · Balance 0 F7: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F9: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on February 17, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F3: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F5: The options are fully vested.

F6: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.

F7: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F8: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F9: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 01, 2021 Filed Jul 3, 2021 01:15 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	57,814	$0.00 Strike: $35.04	$0.00	Disclosure SEC source: 0001179110-21-007353 · edgar.xml · derivative · entry 11 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,186 Underlying: Common Stock · 57,814 shares Expires 2026-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of December 1, 2016 and the remaining shares vested in equal quarterly installments over the following three years thereafter. Read SEC document
July 01, 2021 Filed Jul 3, 2021 01:15 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	9,055	$128.82	$1,166,465.10	Disclosure SEC source: 0001179110-21-007353 · edgar.xml · nonDerivative · entry 6 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,450 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.53 to $129.14 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. Read SEC document
July 01, 2021 Filed Jul 3, 2021 01:15 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	4,560	$127.89	$583,178.40	Disclosure SEC source: 0001179110-21-007353 · edgar.xml · nonDerivative · entry 5 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,505 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.44 to $128.40 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document
July 01, 2021 Filed Jul 3, 2021 01:15 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	23,160	$126.85	$2,937,846.00	Disclosure SEC source: 0001179110-21-007353 · edgar.xml · nonDerivative · entry 4 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,065 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.42 to $127.40 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
July 01, 2021 Filed Jul 3, 2021 01:15 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	9,194	$125.81	$1,156,697.14	Disclosure SEC source: 0001179110-21-007353 · edgar.xml · nonDerivative · entry 3 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,225 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.42 to $126.41 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
July 01, 2021 Filed Jul 3, 2021 01:15 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	11,845	$125.15	$1,482,401.75	Disclosure SEC source: 0001179110-21-007353 · edgar.xml · nonDerivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,419 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.41 to $125.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
July 01, 2021 Filed Jul 3, 2021 01:15 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	57,814	$35.04	$2,025,802.56	Disclosure SEC source: 0001179110-21-007353 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 29, 2021 Filed Feb 3, 2021 00:10 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	64,361	$0.00 Strike: $115.53	$0.00	Disclosure SEC source: 0001179110-21-001116 · edgar.xml · derivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,361 Underlying: Common Stock · 64,361 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2021. Read SEC document
January 29, 2021 Filed Feb 3, 2021 00:10 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	16,662	$0.00	$0.00	Disclosure SEC source: 0001179110-21-001116 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,450 Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	94	$122.55	$11,519.70	Disclosure SEC source: 0001179110-21-000364 · edgar.xml · nonDerivative · entry 5 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,788 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	764	$122.46	$93,559.44	Disclosure SEC source: 0001179110-21-000364 · edgar.xml · nonDerivative · entry 4 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,882 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.18 to $123.09 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	900	$121.55	$109,395.00	Disclosure SEC source: 0001179110-21-000364 · edgar.xml · nonDerivative · entry 3 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,646 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.18 to $122.07 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
January 05, 2021 Filed Jan 6, 2021 23:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	2,500	$120.52	$301,300.00	Disclosure SEC source: 0001179110-21-000364 · edgar.xml · nonDerivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,546 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.99 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
January 04, 2021 Filed Jan 6, 2021 23:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Tax withholdingCommon Stock	3,278	$124.31	$407,488.18	Disclosure SEC source: 0001179110-21-000364 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,046 Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	50,000	$0.00 Strike: $35.04	$0.00	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · derivative · entry 9 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on December 1, 2017, the first anniversary of the grant, and the remainder vest in equal quarterly installments over the three years thereafter. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,100	$99.42	$109,362.00	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · nonDerivative · entry 8 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,324 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.20 to $99.61 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8) to this Form 4. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	4,400	$98.57	$433,708.00	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · nonDerivative · entry 7 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,424 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.18 to $99.08 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	9,534	$97.43	$928,897.62	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · nonDerivative · entry 6 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,824 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.10 to $98.01 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	15,219	$96.49	$1,468,481.31	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · nonDerivative · entry 5 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,358 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.10 to $97.09 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	13,047	$95.85	$1,250,554.95	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · nonDerivative · entry 4 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,577 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.10 to $96.09 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	3,000	$94.46	$283,380.00	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · nonDerivative · entry 3 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,624 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.06 to $94.97 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	3,700	$93.53	$346,061.00	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · nonDerivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,624 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.06 to $94.02 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
July 01, 2020 Filed Jul 6, 2020 22:57 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	50,000	$35.04	$1,752,000.00	Disclosure SEC source: 0001179110-20-008061 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
June 22, 2020 Filed Jun 23, 2020 11:06 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $2.40	$0.00	Disclosure SEC source: 0001544227-20-000031 · wf-form4_159291036057257.xml · derivative · entry 1 Dable Habib J · CIK 0001690773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. Read SEC document
January 22, 2020 Filed Jan 24, 2020 22:18 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	84,720	$0.00 Strike: $52.99	$0.00	Disclosure SEC source: 0001179110-20-000765 · edgar.xml · derivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,720 Underlying: Common Stock · 84,720 shares Expires 2030-01-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2020. Read SEC document
January 22, 2020 Filed Jan 24, 2020 22:18 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	22,173	$0.00	$0.00	Disclosure SEC source: 0001179110-20-000765 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,324 Read SEC document
January 03, 2020 Filed Jan 4, 2020 02:37 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	3,634	$51.24	$186,206.16	Disclosure SEC source: 0001179110-20-000270 · edgar.xml · nonDerivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,151 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.77 to $51.74 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
January 03, 2020 Filed Jan 4, 2020 02:37 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	98	$51.26	$5,023.48	Disclosure SEC source: 0001179110-20-000270 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,785 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.24 to $51.26 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
September 10, 2019 Filed Sep 11, 2019 00:21 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	344	$45.67	$15,710.48	Disclosure SEC source: 0001179110-19-010219 · edgar.xml · nonDerivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,883 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.61 to $45.74 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
September 10, 2019 Filed Sep 11, 2019 00:21 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	5,281	$45.20	$238,701.20	Disclosure SEC source: 0001179110-19-010219 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,227 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.51 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
June 20, 2019 Filed Jun 21, 2019 20:34 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $11.59	$0.00	Disclosure SEC source: 0001209191-19-038478 · doc4.xml · derivative · entry 1 Dable Habib J · CIK 0001690773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document
April 09, 2019 Filed Apr 11, 2019 20:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	146	$44.23	$6,457.58	Disclosure SEC source: 0001179110-19-004910 · edgar.xml · nonDerivative · entry 3 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,508 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 09, 2019 Filed Apr 11, 2019 20:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	100	$45.46	$4,546.00	Disclosure SEC source: 0001179110-19-004910 · edgar.xml · nonDerivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,654 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 09, 2019 Filed Apr 11, 2019 20:58 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	7,214	$44.60	$321,744.40	Disclosure SEC source: 0001179110-19-004910 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,754 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.09 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
January 25, 2019 Filed Jan 29, 2019 22:37 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	106,400	$0.00 Strike: $41.64	$0.00	Disclosure SEC source: 0001179110-19-001052 · edgar.xml · derivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,400 Underlying: Common Stock · 106,400 shares Expires 2029-01-25 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019. Read SEC document
January 25, 2019 Filed Jan 29, 2019 22:37 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	17,700	$0.00	$0.00	Disclosure SEC source: 0001179110-19-001052 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,968 Read SEC document
January 15, 2019 Filed Jan 17, 2019 21:45 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001209191-19-004231 · doc4.xml · derivative · entry 1 Dable Habib J · CIK 0001690773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document
January 03, 2019 Filed Jan 4, 2019 23:34 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	27	$40.85	$1,102.95	Disclosure SEC source: 0001179110-19-000467 · edgar.xml · nonDerivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,268 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 03, 2019 Filed Jan 4, 2019 23:34 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,930	$43.45	$83,858.50	Disclosure SEC source: 0001179110-19-000467 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,295 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
December 07, 2018 Filed Dec 12, 2018 00:36 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantStock Option (right to buy) · Derivative	14,880	Not disclosed Strike: $16.40	Not disclosed	Disclosure SEC source: 0001209191-18-062107 · doc4.xml · derivative · entry 1 Dable Habib J · CIK 0001690773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,880 Underlying: Common Stock · 14,880 shares Expires 2028-09-20 F2 · price: Received in connection with the merger of Millendo Therapeutics, Inc. ("Millendo") into the Issuer in exchange for a stock option to acquire 200,000 shares of Millendo common stock for $1.22 per share. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on September 21, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
December 04, 2018 Filed Dec 6, 2018 21:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	700	$54.33	$38,031.00	Disclosure SEC source: 0001179110-18-013519 · edgar.xml · nonDerivative · entry 4 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,225 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.20 to $54.41 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document
December 04, 2018 Filed Dec 6, 2018 21:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	5,607	$53.65	$300,815.55	Disclosure SEC source: 0001179110-18-013519 · edgar.xml · nonDerivative · entry 3 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,925 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.19 to $54.12 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
December 04, 2018 Filed Dec 6, 2018 21:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	3,862	$52.72	$203,604.64	Disclosure SEC source: 0001179110-18-013519 · edgar.xml · nonDerivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,532 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.15 to $53.14 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
December 04, 2018 Filed Dec 6, 2018 21:22 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	2,506	$51.54	$129,159.24	Disclosure SEC source: 0001179110-18-013519 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,394 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.12 to $51.95 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
March 01, 2018 Filed Mar 5, 2018 22:13 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	108,800	$0.00 Strike: $40.61	$0.00	Disclosure SEC source: 0001179110-18-003493 · edgar.xml · derivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,800 Underlying: Common Stock · 108,800 shares Expires 2028-03-01 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018. Read SEC document
March 01, 2018 Filed Mar 5, 2018 22:13 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	18,100	$0.00	$0.00	Disclosure SEC source: 0001179110-18-003493 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,900 Read SEC document
December 01, 2016 Filed Dec 5, 2016 21:16 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	400,000	$0.00 Strike: $35.04	$0.00	Disclosure SEC source: 0001179110-16-032369 · edgar.xml · derivative · entry 2 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2026-12-01 F1 · derivative.exercise_date: The shares of registrant's common stock underlying this stock option award vest as to 25% of the shares on the first anniversary of the grant and in equal quarterly installments over the three years thereafter. Read SEC document
December 01, 2016 Filed Dec 5, 2016 21:16 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	62,800	$0.00	$0.00	Disclosure SEC source: 0001179110-16-032369 · edgar.xml · nonDerivative · entry 1 Dable Habib J · CIK 0001690773 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,800 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.